Organon & Co | OGN - Des Atouts





Des Atouts Changement Date
Bristol-Myers Squibb USD 86.48B 3.56B 2026-03
Celltrion KRW 768.81B 9.37B 2026-03
Cspc Pharmaceutical CNY 46.7B 695.56M 2025-12
Deva Holding AS TRY 12.93B 1.83B 2023-09
Dianthus Therapeutics USD 1.25B 715.96M 2026-03
Divis Laboratories Ltd INR 200.33B 18.82B 2026-03
Gilead Sciences USD 56.28B 2.74B 2026-03
Glaxosmithkline GBP 62.87B 19.47B 2026-03
Kangmei Pharma CNY 13.31B 375.64M 2026-03
Knight Therapeutics CAD 1.05B 2.28M 2025-12
Laboratorios Farma EUR 799.88M 99.95M 2023-12
Malin Corporation EUR 198.5M 70.1M 2024-12
Medical Developments International AUD 63.57M 2.83M 2025-12
Merck USD 128.68B 8.18B 2026-03
Neuren Pharmaceuticals AUD 342.86M 11.61M 2025-12
Novartis USD 118.53B 7.58B 2026-03
Organigram Holdings CAD 521.31M 9.36M 2026-03
Organon & Co USD 13B 129M 2026-03
Ovoca Bio EUR 1.66M 9.75M 2025-06
Pharma Mar EUR 385.26M 9.82M 2026-03
Qiagen NV USD 6.3B 257.54M 2025-12
Sartorius EUR 9.87B 154.9M 2026-03
Sino Biopharmaceutical CNY 74.89B 9.49B 2025-06
Tilray USD 2.1B 15.95M 2025-09
Zealand Pharma A/S 15.95B 848.45M 2025-12